Related Experiment Video
Updated: Oct 4, 2025
05:58
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
324
Biochanin A Attenuates Cardiomyopathy in Type 2 Diabetic Rats by Increasing SIRT1 Expression and Reducing Oxidative
Manisha J Oza1,2, Yogesh A Kulkarni1
1Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V. L. Mehta Road, Vile Parle (W), Mumbai, 400056, India.
Chemistry & Biodiversity
|February 4, 2022
Summary
Biochanin A effectively combats diabetic cardiomyopathy in type 2 diabetes by reducing cardiac markers, oxidative stress, and improving SIRT1 expression. This natural compound shows potential for managing diabetic heart complications.
Area of Science:
- Biochemistry
- Pharmacology
- Cardiology
Background:
- Diabetic cardiomyopathy is a significant complication of type 2 diabetes, leading to myocardial abnormalities and increased morbidity.
- Biochanin A, a methylated isoflavone from Trifolium pratense, possesses known anti-inflammatory, antioxidant, and anti-diabetic properties.
Purpose of the Study:
- To evaluate the therapeutic efficacy of Biochanin A in mitigating type 2 diabetic cardiomyopathy.
- To investigate the effects of Biochanin A on cardiac function, oxidative stress, and SIRT1 expression in a rat model.
Main Methods:
- Type 2 diabetes was induced in rats using a high-fat diet and streptozotocin.
- Animals were treated orally with Biochanin A (10, 20, 40 mg/kg) for 16 weeks.
- Cardiac markers, blood glucose, oxidative stress, hemodynamic parameters, histopathology, and SIRT1 expression were assessed.
Main Results:
- Biochanin A treatment significantly reduced plasma cardiac markers, hyperglycemia, hyperlipidemia, and cardiac oxidative stress.
- Improved hemodynamic parameters and increased SIRT1 expression in cardiac tissue were observed.
- Histopathological analysis confirmed reduced cardiac hypertrophy and demonstrated cardioprotective effects.
Conclusions:
- Biochanin A demonstrates potential in controlling hyperglycemia, oxidative stress, and enhancing SIRT1 expression in cardiac tissue.
- Biochanin A may serve as a promising therapeutic candidate to manage the progression of cardiomyopathy in type 2 diabetes mellitus.
